1,201 results on '"Blank, Christian"'
Search Results
2. Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma
3. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells
4. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
5. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
6. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
7. Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance
8. The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022
9. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
10. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial
11. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021
12. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
13. Electronic patient-reported outcomes, fever management, and symptom prediction among patients with BRAF V600 mutant stage III–IV melanoma: The Kaiku Health platform
14. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
15. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response
16. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study
17. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
18. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
19. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
20. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome
21. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
22. Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery
23. B cells and tertiary lymphoid structures promote immunotherapy response
24. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials
25. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry
26. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma
27. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
28. Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.
29. The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.
30. A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma
31. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
32. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
33. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
34. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)
35. The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021
36. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
37. MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance
38. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
39. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
40. A prediction model for response to immune checkpoint inhibition in advanced melanoma
41. BRAF/MEK inhibitor rechallenge in advanced melanoma patients
42. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series
43. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer
44. Metabolic profiles of regulatory T cells in the tumour microenvironment
45. Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome
46. End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study
47. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
48. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
49. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
50. Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.